TABLE 2.

Effect of the interventions on plasma total cholesterol, LDL-c, non-HDL-c, REM-c, triglycerides, and HDL-c over the 8-week treatment period.

	Placebo		Ezetimibe		Nutraceutical		Combination		Main effects P-value		Interactive P-value
	Week 0	Week 8	Week 0	Week 8	Week 0	Week 8	Week 0	Week 8	Ezetimibe	Nutraceutical
Total cholesterol (mmol/L)	7.15 ± 0.38	7.49 ± 0.36	7.12 ± 0.24	6.24 ± 0.23	6.66 ± 0.33	5.56 ± 0.29	7.18 ± 0.33	5.27 ± 0.35	<0.0001	<0.0001	0.275
LDL-c (mmol/L)	4.86 ± 0.32	5.01 ± 0.31	4.89 ± 0.25	4.01 ± 0.20	4.41 ± 0.24	3.54 ± 0.16	5.01 ± 0.31	3.32 ± 0.13	<0.0001	<0.0001	0.631
Non-HDL-c (mmol/L)	5.77 ± 0.40	6.11 ± 0.39	5.75 ± 0.27	4.81 ± 0.26	5.36 ± 0.38	4.41 ± 0.27	5.94 ± 0.34	3.98 ± 0.28	<0.0001	<0.0001	0.267
REM-c (mmol/L)	0.91 ± 0.15	1.10 ± 0.20	0.85 ± 0.13	0.80 ± 0.08	0.93 ± 0.13	0.86 ± 0.09	0.86 ± 0.08	0.66 ± 0.07	0.076	0.129	0.469
Triglycerides (mmol/L)	2.08 ± 0.36	2.50 ± 0.31	1.87 ± 0.28	1.74 ± 0.18	2.19 ± 0.27	1.93 ± 0.18	1.77 ± 0.15	1.44 ± 0.15	0.096	0.191	0.435
HDL-c (mmol/L)	1.39 ± 0.11	1.38 ± 0.09	1.38 ± 0.08	1.43 ± 0.07	1.24 ± 0.13	1.15 ± 0.16	1.37 ± 0.10	1.29 ± 0.13	0.107	0.053	0.912

Mean ± SEM. HDL-c, high-density lipoprotein cholesterol; LDL-c, low-density lipoprotein cholesterol; REM-c, remnant cholesterol.